TY - JOUR
T1 - Implementation of pharmacogenetics
T2 - The University of Maryland personalized anti-platelet pharmacogenetics program
AU - Shuldiner, Alan R.
AU - Palmer, Kathleen
AU - Pakyz, Ruth E.
AU - Alestock, Tameka D.
AU - Maloney, Kristin A.
AU - O'Neill, Courtney
AU - Bhatty, Shaun
AU - Schub, Jamie
AU - Overby, Casey Lynnette
AU - Horenstein, Richard B.
AU - Pollin, Toni I.
AU - Kelemen, Mark D.
AU - Beitelshees, Amber L.
AU - Robinson, Shawn W.
AU - Blitzer, Miriam G.
AU - Mcardle, Patrick F.
AU - Brown, Lawrence
AU - Jeng, Linda Jo Bone
AU - Zhao, Richard Y.
AU - Ambulos, Nicholas
AU - Vesely, Mark R.
PY - 2014/3
Y1 - 2014/3
N2 - Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non-trivial practical barriers. We implemented a Personalized Anti-platelet Pharmacogenetics Program (PAP3) for cardiac catheterization patients at the University of Maryland Medical Center and the Baltimore Veterans Administration Medical Center Patients' are offered CYP2C19 genetic testing, which is performed in our Clinical Laboratory Improvement Amendment (CLIA)-certified Translational Genomics Laboratory. Results are returned within 5hr along with clinical decision support that includes interpretation of results and prescribing recommendations for anti-platelet therapy based on the Clinical Pharmacogenetics Implementation Consortium guidelines. Now with a working template for PAP3, implementation of other drug-gene pairs is in process. Lessons learned as described in this article may prove useful to other medical centers as they implement pharmacogenetics into patient care, a critical step in the pathway to personalized and genomic medicine.
AB - Despite a substantial evidence base, implementation of pharmacogenetics into routine patient care has been slow due to a number of non-trivial practical barriers. We implemented a Personalized Anti-platelet Pharmacogenetics Program (PAP3) for cardiac catheterization patients at the University of Maryland Medical Center and the Baltimore Veterans Administration Medical Center Patients' are offered CYP2C19 genetic testing, which is performed in our Clinical Laboratory Improvement Amendment (CLIA)-certified Translational Genomics Laboratory. Results are returned within 5hr along with clinical decision support that includes interpretation of results and prescribing recommendations for anti-platelet therapy based on the Clinical Pharmacogenetics Implementation Consortium guidelines. Now with a working template for PAP3, implementation of other drug-gene pairs is in process. Lessons learned as described in this article may prove useful to other medical centers as they implement pharmacogenetics into patient care, a critical step in the pathway to personalized and genomic medicine.
KW - Anti-platelet pharmacogenetics
KW - CYP2C19
KW - Clopidogrel
KW - Implementation science
KW - Individualized medicine
KW - Personalized medicine
KW - Pharmacogenomics
KW - Translational research
UR - http://www.scopus.com/inward/record.url?scp=84896319906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896319906&partnerID=8YFLogxK
U2 - 10.1002/ajmg.c.31396
DO - 10.1002/ajmg.c.31396
M3 - Article
C2 - 24616408
AN - SCOPUS:84896319906
SN - 1552-4868
VL - 166
SP - 76
EP - 84
JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
IS - 1
ER -